ASCO 2019 | CAR need an upgrade?
Nirav Niranjan Shah
• 3 Jun 2019
Although CAR T-cell therapy is a vast improvement on previous treatments, there is plenty of room for improvement. Speaking at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting in Chicago, IL, Nirav Niranjan Shah, MD, of the Medical College of Wisconsin, Milwaukee, WI, discusses how the potential to target two antigens on non-Hodgkin lymphomas could further improve clinical outcomes.
